Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 5,081 recruiting studies in this area right now.
By phase
- Not applicable2,108
- Phase 21,115
- Phase 1823
- Phase 1/Phase 2481
- Phase 3348
- Phase 4127
- Phase 2/Phase 379
Top conditions
- Multiple Myeloma332
- Acute Myeloid Leukemia292
- Lymphoma182
- Sickle Cell Disease140
- Myelodysplastic Syndromes129
- Acute Lymphoblastic Leukemia122
- Chronic Lymphocytic Leukemia100
- Leukemia100
- Follicular Lymphoma74
- Hematologic Malignancy68
- Myelodysplastic Syndrome68
- Hodgkin Lymphoma67
- Mantle Cell Lymphoma62
- Anemia60
- Diffuse Large B Cell Lymphoma57
- Lymphedema50
- Non-Hodgkin Lymphoma49
- Small Lymphocytic Lymphoma49
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China148
- M.D. Anderson Cancer Center147
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University68
- Memorial Sloan Kettering Cancer Center64
- City of Hope Medical Center61
- Mayo Clinic61
- Assistance Publique - Hôpitaux de Paris46
- St. Jude Children's Research Hospital43
- Peking University People's Hospital41
Where studies are running
- California406
- Texas186
- Maryland149
- Alabama148
- Arizona124
- Florida110
- Massachusetts101
- New York98
- Ohio70
- Minnesota68
Recruiting studies5,081 total
- NCT06251076RecruitingPhase 4
Outpatient teclistamab for multiple myeloma: a safety study
This study tests whether giving the drug teclistamab (a treatment for multiple myeloma) in an outpatient setting is safe and works well. You may qualify if you have had at least three prior treatments, have a caregiver to support you, and meet other health criteria.
Toronto, OntarioAges 18 years+ - NCT06251180RecruitingPhase 1
Rocbrutinib plus R-CHOP for newly diagnosed B-cell lymphoma
This trial tests a new targeted drug called rocbrutinib combined with the standard chemo-immunotherapy R-CHOP for people newly diagnosed with certain types of B-cell non-Hodgkin lymphoma. The goal is to see if adding rocbrutinib helps the standard treatment work better.
Guangzhou, GuangdongAges 18–70 - NCT06252298RecruitingPhase 1
Testing a new drug for CD38-positive blood cancers
This trial tests a new drug, SCTC21C, for people with certain blood cancers (like myeloma or lymphoma) that have come back or not responded to other treatments. The goal is to see if the drug is safe and can help control the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06252792Recruiting
Daratumumab-pomalidomide-dexamethasone for first-relapse myeloma
This trial tests a combination of three drugs (daratumumab, pomalidomide, and dexamethasone) for people whose multiple myeloma has returned for the first time after initial treatment with RVD. The goal is to see if this new combination can control the cancer.
Changchun, JilinAges 18 years+ - NCT06252675RecruitingPhase 2
Glofitamab and pirtobrutinib for relapsed mantle cell lymphoma
This study tests a combination of two drugs—glofitamab (given as an infusion) and pirtobrutinib (a pill)—for people with mantle cell lymphoma that has come back or not responded to previous treatment. The goal is to see if the combo works better than either drug alone.
Davis, CaliforniaAges 18 years+ - NCT06252870RecruitingPhase 2
Comparing two conditioning regimens for stem cell transplant
This trial tests two different chemotherapy and radiation plans (conditioning regimens) given before a stem cell transplant from a matched donor. Both are followed by the same drugs to prevent graft-versus-host disease. The goal is to find which regimen works better for people with blood cancers.
AngersAges 18–70 - NCT06254560RecruitingPhase 2
Rituximab for severe aplastic anemia with platelet transfusion problems
This study tests if the drug rituximab can help people with severe aplastic anemia whose bodies have stopped responding to platelet transfusions. It aims to see if rituximab can improve the body's ability to accept platelets again.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT06256627Recruiting
Maintenance treatment of 'ITIVA' for AML in remission
This trial tests a maintenance treatment called 'ITIVA' for people with acute myeloid leukemia (AML) who have achieved remission after initial chemotherapy and consolidation therapy. The goal is to see if this treatment helps keep the leukemia from coming back.
Zhengzhou, HenanAges 14 years+ - NCT06259292Recruiting
HHT patient registry tracking long-term outcomes
This registry collects health information from people with HHT over time to better understand the disease and improve care. Joining does not involve any experimental treatment, but your data will help researchers learn more about HHT.
Birmingham, AlabamaAges Any age - NCT06260111Recruiting
Laser therapy for mouth sores during stem cell transplant
This study tests whether a special light therapy (photobiomodulation) can reduce painful mouth sores and help you eat, drink, and speak better during a stem cell transplant. It is for adults with blood cancers who are having a stem cell transplant.
Santiago, Santiago MetropolitanAges 18–65 - NCT06260891RecruitingPhase 2
Zinc study for sickle cell disease and bone health
This study tests if taking zinc supplements can improve bone health in people with sickle cell disease. It's for those with certain types of sickle cell disease (SS or S-Beta zero thalassemia) who are not on chronic transfusions or zinc supplements.
Oakland, CaliforniaAges 15–40 - NCT06263387Recruiting
Study of venetoclax and azacitidine for untreated AML patients
This trial looks at how well the combination of venetoclax and azacitidine works for people with newly diagnosed AML who cannot have strong chemotherapy. It is a real-world study of patients already getting this treatment through a special program in France.
AmiensAges 18 years+ - NCT06263530Recruiting
Blood test for tumor DNA in Hodgkin lymphoma
This study looks at whether a blood test that checks for tiny pieces of tumor DNA (called ctDNA) can help predict how Hodgkin lymphoma will progress. It is for adults who have just been diagnosed with classical Hodgkin lymphoma.
Hradec KrálovéAges 18 years+ - NCT06263491RecruitingPhase 2
Pirtobrutinib and Rituximab for Low/Medium Risk MCL
This trial tests a combination of two medications, pirtobrutinib and rituximab, for people newly diagnosed with low- or medium-risk mantle cell lymphoma. It aims to see if this approach is effective and safe without needing chemotherapy.
Houston, TexasAges 18 years+ - NCT06265584RecruitingPhase 2
Using ATG to prevent graft-versus-host disease after stem cell transplant
This trial tests if a two-step course of a drug called ATG (anti-thymocyte globulin) can help prevent a serious side effect called graft-versus-host disease (GVHD) after a donor stem cell transplant. It is for people with certain blood cancers who are receiving a reduced-intensity transplant.
Birmingham, AlabamaAges 18–75 - NCT06265870Recruiting
Targeted vs. General Antiparasitic Treatment for High Eosinophils
This study compares a specific antiparasitic treatment to a general one for people with high eosinophil levels (a type of white blood cell). If you have eosinophilia without an obvious cause, you may be assigned to receive either a targeted drug or a broader treatment to see which works better.
Hat Yai, Changwat SongkhlaAges 18 years+ - NCT06270498RecruitingPhase 4
Oral iron for heart failure: exercise and quality of life study
This study tests whether an oral iron supplement (a pill called sucrosomial iron) can help people with heart failure who have low iron feel better, have more energy, and walk farther. Participants will take the iron pill or a placebo (a pill without the active ingredient) for a period and will do exercise tests and answer questionnaires to see how they improve.
Pisa, TuscanyAges 18 years+ - NCT06270888RecruitingPhase 1
Shorter radiation treatment for multiple myeloma
This trial tests a shorter course of radiation therapy for up to 5 bone lesions that have come back or not responded to treatment. It aims to see if this approach is safe and helps control the disease.
Chicago, IllinoisAges 18 years+ - NCT06270667Recruiting
Exercise training for lymphoma survivors
This study tests whether a supervised exercise program can improve heart health in people who finished treatment for Hodgkin or aggressive non-Hodgkin lymphoma 2–5 years ago. The goal is to see if regular exercise helps your heart recover better after chemotherapy or chest radiation.
OsloAges 20–70 - NCT06270771Recruiting
Using a wearable ring to monitor MDS patients at home
This study tests if people with MDS can comfortably wear the OURA ring (a smart ring) at home to track their health. The goal is to see if this is a useful way to monitor symptoms and well-being between doctor visits.
Toronto, OntarioAges 18 years+ - NCT06271252RecruitingPhase 1
Study of OriCAR-017 for relapsed or refractory multiple myeloma
This trial tests a new type of CAR-T cell therapy called OriCAR-017 for people with multiple myeloma that has come back or not responded to treatment. It is for patients who have already tried several treatments, including ones that target BCMA, and their last treatment stopped working.
Atlanta, GeorgiaAges 18–75 - NCT06271512Recruiting
Follow-up study for beta-thalassemia patients treated with beti-cel
This study is for people with beta-thalassemia who have already received the gene therapy betibeglogene autotemcel (beti-cel). It collects information to learn how patients are doing after this treatment in real-world settings.
Oakland, CaliforniaAges Any age - NCT06275022Recruiting
Using ICG dye to guide treatment of facial birthmarks
This study tests whether a special dye called ICG can help doctors treat a type of facial birthmark called capillary lymphatic malformation (cLM) more effectively. It may help by showing the birthmark more clearly during treatment.
Nanjing, JiangsuAges 4 weeks–16 years - NCT06279026Recruiting
Testing UTAA17 for advanced multiple myeloma
This trial tests a new treatment called UTAA17 that targets a protein on myeloma cells. It may be an option for people whose multiple myeloma has not responded to several prior treatments.
Suzhou, JiangsuAges 18 years+
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 5,081 recruiting hematology studies from the U.S. registry right now, out of 7,739 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.